Tag:

Robert Davis

Deadly Shooting: 26-Year-Old CT Man ID'd As Victim Deadly Shooting: 26-Year-Old CT Man ID'd As Victim
Deadly Shooting: 26-Year-Old CT Man ID'd As Victim A 26-year-old Connecticut man who was shot and killed over the weekend has been identified by police. The shooting took place in New Haven County around 5 a.m., Sunday, June 4, between North Main Street at Division Street in Waterbury. According to Lt. Robert Davis of the Waterbury Police, officers responded to the area of the shooting and found an unoccupied vehicle and evidence of a shooting. The victim, identified as Akeem Campbell, of Waterbury, was taken by private car to St. Vincent's Hospital where he was pronounced dead, Davis said. This incident remains under investigation b…
COVID-19: FDA Authorizes Second Antiviral Pill COVID-19: FDA Authorizes Second Antiviral Pill
Covid-19: FDA Authorizes Second Antiviral Pill For the second time in as many days, the Food and Drug Administration (FDA) has authorized the use of an antiviral pill to treat mild and moderate COVID-19 cases. On Thursday, Dec. 23, the FDA approved the use of Merck’s molnupiravir pill for emergency use authorization, a day after officials authorized the use of Pfizer’s COVID-19 treatment pill. Earlier story - COVID-19: FDA OKs First Authorized Home Treatment For Virus Merck’s pill has been cleared for use by adults 18 and older who have tested positive for COVID-19 and are at the greatest risk of being hospitalized or dying from t…
COVID-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus COVID-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus
Covid-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus A new pharmaceutical company is throwing its hat in the ring as the country continues its fight against COVID-19. Merck and Ridgeback Biotherapeutics announced on Friday, Oct. 1 that it is planning to apply for federal emergency approval of a pill that can reportedly help prevent hospitalizations and deaths in COVID-19 patients. According to the company, trials have found that the pill - dubbed molnupiravir - could potentially reduce the risk of hospitalization or death in patients with mild to moderate COVID-19 by approximately 50 percent. The results of the late-stage trial have bee…